Skip to search formSkip to main contentSkip to account menu

Valtorcitabine

Known as: 3'-VAL-L-DC, L-Valine, 3'-Ester with 2'-Deoxycytidine 
An orally active prodrug of torcitabine (L-deoxycytidine), a nucleoside analog with activity against hepatitis B virus. Torcitabine is modified in… 
National Institutes of Health

Related topics

Related topics

1 relation
Valtorcitabine Dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Clinical trial results of new therapies for HBV: implications for treatment guidelines.
  • R. Gish
  • Seminars in liver disease (Print)
  • 2005
  • Corpus ID: 45683359
Currently approved treatments for chronic infection with hepatitis B virus (HBV) are limited by low rates of sustained response… 
2005
2005
Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B
Review
2004
Review
2004
Telbivudine/Torcitabine Idenix/Novartis.
Idenix (formerly Novirio) and Novartis are developing two beta-L-deoxynucleosides, telbivudine and torcitabine, for the potential… 
2004
2004
Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)